Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance

被引：0
|
作者：
C Palmieri
O Gojis
B Rudraraju
C Stamp-Vincent
D Wilson
S Langdon
C Gourley
D Faratian
机构：
[1] Institute of translational Medicine,Department of Molecular and Clinical Cancer Medicine
[2] University of Liverpool,Division of Cancer
[3] Cancer Research UK Laboratories,Edinburgh Breakthrough Research Unit and Division of Pathology
[4] Imperial College London,undefined
[5] Du Cane Road,undefined
[6] London,undefined
[7] UK,undefined
[8] University of Edinburgh,undefined
[9] University of Edinburgh Cancer Research UK Centre,undefined
[10] Institute of Genetics and Molecular Medicine,undefined
[11] University of Edinburgh,undefined
来源：
British Journal of Cancer | 2013年 / 108卷
关键词：
ovarian cancer; SRC3; platinum; resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2039 / 2044
页数：5
相关论文
共 50 条
  • [21] Co-expression of CD44/MyD88 is a poor prognostic factor in advanced epithelial ovarian cancer
    Zhu, Yi
    Zhang, Hongtao
    Zhang, Guonan
    Shi, Yu
    Huang, Jianming
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (05)
  • [22] Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer
    Li-yuan Feng
    Li Li
    Journal of Ovarian Research, 13
  • [23] Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity
    Baba, Tsukasa
    Mori, Seiichi
    Matsumura, Noriomi
    Kariya, Masatoshi
    Murphy, Susan K.
    Kondoh, Eiji
    Kusakari, Takashi
    Kuroda, Hideki
    Mandai, Masaki
    Higuchi, Toshihiro
    Takakura, Kenji
    Fukuda, Michiko N.
    Fujii, Shingo
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 360 (02) : 363 - 369
  • [24] Dihydrofolate reductase as a predictor for poor response to platinum-based chemotherapy in epithelial ovarian cancer
    Wang, Min
    Hu, Ting
    Xie, Ke-Yu
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2019, 12 (05): : 1723 - 1730
  • [25] EXPRESSION OF P-GLYCOPROTEIN IN EPITHELIAL OVARIAN-CANCER - EVALUATION AS A MARKER OF MULTIDRUG RESISTANCE
    RUBIN, SC
    FINSTAD, CL
    HOSKINS, WJ
    SAIGO, PE
    PROVENCHER, DM
    FEDERICI, MG
    HAKES, TB
    MARKMAN, M
    REICHMAN, BS
    LLOYD, KO
    LEWIS, JL
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1990, 163 (01) : 69 - 73
  • [26] Trefoil factor 3 expression in epithelial ovarian cancer exerts a minor effect on clinicopathological parameters
    Hoellen, Friederike
    Kostara, Athina
    Karn, Thomas
    Holtrich, Uwe
    El-Balat, Ahmed
    Otto, Mike
    Rody, Achim
    Hanker, Lars C.
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (04) : 422 - 428
  • [27] The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer
    Bartlett, JMS
    Langdon, SP
    Simpson, BJB
    Stewart, M
    Katsaros, D
    Sismondi, P
    Love, S
    Scott, WN
    Williams, ARW
    Lessells, AM
    Macleod, KG
    Smyth, JF
    Miller, WR
    BRITISH JOURNAL OF CANCER, 1996, 73 (03) : 301 - 306
  • [28] Urokinase-type plasminogen activator in epithelial ovarian cancer: A poor prognostic factor, associated with advanced stage
    Chambers, SK
    Ivins, CM
    Carcangiu, ML
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1998, 8 (03) : 242 - 250
  • [29] Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients
    Anna Felisiak-Golabek
    Alina Rembiszewska
    Iwona K Rzepecka
    Lukasz Szafron
    Radoslaw Madry
    Magdalena Murawska
    Tomasz Napiorkowski
    Piotr Sobiczewski
    Beata Osuch
    Jolanta Kupryjanczyk
    Journal of Ovarian Research, 4
  • [30] Steroid receptor coactivator-3 as a potential molecular target for cancer therapy
    Tien, Jean Ching-Yi
    Xu, Jianming
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (11) : 1085 - 1096
12345